Vertex Pharmaceuticals (VRTX) Notes Payables (2010 - 2017)
Vertex Pharmaceuticals (VRTX) posted quarterly Notes Payables of $232.4 million for Q4 2017, up 216.55% year-over-year from $73.4 million in Q4 2016, and up 22.14% quarter-over-quarter from $190.3 million in Q3 2017.
Vertex Pharmaceuticals (VRTX) Notes Payables (2010 - 2017) Analysis & Trends
Vertex Pharmaceuticals' Notes Payables history runs 4 years deep, the most recent figure standing at $232.4 million for Q4 2017.
- In Q4 2017, Notes Payables rose 216.55% year-over-year to $232.4 million; the TTM figure through Dec 2017 stood at $232.4 million (up 216.55% YoY), while the FY2017 annual figure was $232.4 million, up 216.55% from the prior year.
- Notes Payables for Q4 2017 stood at $232.4 million, up from $190.3 million in the prior quarter.
- The five-year high for Notes Payables was $232.4 million in Q4 2017, with the low at $73.4 million in Q4 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | 232.40 Mn |
| Sep 30, 2017 | 190.27 Mn |
| Jun 30, 2017 | 147.69 Mn |
| Mar 31, 2017 | 104.77 Mn |
| Dec 31, 2016 | 73.42 Mn |
| Sep 30, 2011 | 94.16 Mn |
| Mar 31, 2011 | 84.89 Mn |
| Dec 31, 2010 | 77.80 Mn |